Leukemia drug passes final trial phase with flying colors
A medication to treat chronic myeloid leukemia (CML) has shown its potential to become the new frontline therapy for people living with the life-threatening blood cancer.
Jun 4, 2024
0
1
A medication to treat chronic myeloid leukemia (CML) has shown its potential to become the new frontline therapy for people living with the life-threatening blood cancer.
Jun 4, 2024
0
1
According to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) achieved similar clinical outcomes ...
Jun 4, 2024
0
0
People battling advanced colon cancers might have a new treatment option that could extend their survival, a new trial finds. The findings were present the at the annual meeting of the American Society of Clinical Oncology ...
May 29, 2024
0
0
A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall ...
May 24, 2024
0
2
A U.S. Food and Drug Administration committee voted unanimously in April to approve a new clinical endpoint, minimal residual disease (MRD), when evaluating proposed drugs to treat multiple myeloma.
May 22, 2024
0
2
For patients with solid tumors, assignment to an experimental group in trials of investigational drugs yields significant survival gains, according to a review published online April 30 in the Annuals of Internal Medicine.
Apr 30, 2024
0
0
For patients with advanced adrenocortical carcinoma, cabozantinib shows promising efficacy, according to a study published online April 9 in The Lancet Oncology.
Apr 29, 2024
0
1
New research from the University of Pittsburgh explains why metastatic uveal melanoma is resistant to conventional immunotherapies and how adoptive therapy, which involves growing a patient's T cells outside the body before ...
Apr 16, 2024
0
55
Patient prognosis and treatment response prediction are key factors in treating ovarian cancer, which is characterized by the lowest survival rate among gynecological cancers. Consequently, there is strong demand for a more ...
Apr 15, 2024
0
0
The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Apr 10, 2024
0
1